|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-2.81/-3.64
|
企業價值
2.95B
|
資產負債 |
每股賬面淨值
10.46
|
現金流量 |
現金流量率
--
|
損益表 |
收益
0
|
每股收益
0.00
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/12/23 22:16 EST
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada. |